Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX™ in Patients with Ménière’s Disease

Back to Jobs

Missed primary endpoint (p value = 0.62) and all key vertigo secondary endpoints Company to immediately suspend all development activities for OTIVIDEX Company is also undertaking a review of its product pipeline plans and commercial efforts in order to identify opportunities to extend its cash

Apply Now